06-18-2020, 05:21 PM
![[Image: medicaid.gov.jpg?1390320339]](https://content.govdelivery.com/system/images/39825/original/medicaid.gov.jpg?1390320339)
In Case You Missed It:
Health Affairs Blog by CMS Administrator
Seema Verma - CMS’s Proposed Rule On
Value-Based Purchasing For Prescription Drugs:
New Tools For Negotiating Prices For
The Next Generation of Therapies
Medicaid.gov sent this bulletin at 06/18/2020 11:44 AM EDT
Contact: CMS Media Relations
(202) 690-6145 | CMS Media Inquiries
CMS’s Proposed Rule On Value-Based Purchasing
For Prescription Drugs: New Tools For Negotiating Prices
For The Next Generation of Therapies
to lower the price of drugs and spur greater competition and innovation
in the American health care system. As a result of actions by the Centers
for Medicare and Medicaid Services (CMS), the average basic premium for
Medicare Part D prescription drug plans was projected
to decline 13.5 percent since 2017, to the lowest level in seven years,
saving beneficiaries about $1.9 billion in premium costs over that time.
Most recently, in March, CMS announced the Senior Savings Model, where
participating enhanced Part D prescription drug plans across the country
will provide Medicare beneficiaries access to a broad set of insulins at a
maximum $35 copay for a month’s supply, saving beneficiaries on
average 66 percent per year.
Today, we are announcing another significant step in this fight through
a proposed overhaul of Medicaid regulations that have long inhibited
payment innovation among prescription drugs across the entire system.
To read the full Health Affairs blog, go to:
https://www.healthaffairs.org/do/10.1377/hblog20200617.728496/full/